ABIOGEN PHARMA S.P.A.

Siamo orgogliosi di annunciare la nostra partecipazione, come co-fondatori, alla nascita di Ambros Therapeutics, nuova biotech americana dedicata allo sviluppo del neridronato per il trattamento della CRPS-1, Sindrome Dolorosa Regionale Complessa di tipo 1 (Algodistrofia), una patologia rara e debilitante. Il progetto rappresenta un passaggio strategico nella valorizzazione internazionale di una molecola scoperta e sviluppata da Abiogen Negli Stati Uniti, dove ad oggi non esistono terapie approvate per la CRPS-1, il neridronato ha ottenuto dalla FDA le designazioni di Breakthrough Therapy, Fast Track e Orphan Drug, con un'accelerazione del percorso regolatorio. «Con Ambros compiamo un passo decisivo nel nostro percorso», dichiara Massimo Di Martino, Presidente di Abiogen Pharma. «Il nostro obiettivo è rendere disponibile una terapia innovativa a pazienti affetti da una patologia rara con un elevato bisogno clinico insoddisfatto». #AbiogenPharma #AmbrosTherapeutics #neridronato #RicercaClinica https://lnkd.in/eZjtjhZf

At Abiogen Pharma, we combine decades of pharmaceutical expertise with cutting-edge capabilities to deliver flexible, high-quality CDMO services tailored to your needs. From R&D to commercial production, our integrated solutions ensure efficiency, compliance, and innovation at every stage of the value chain. Whether you are a startup or an established pharma company, Abiogen is your reliable partner to bring therapies to life. ✅ State-of-the-art facilities ✅ End-to-end support (development, manufacturing, packaging) ✅ Fast implantation of multiple pharmaceutical form and formulations ✅ A partner committed to quality and trust Let’s shape the future of healthcare, together. 🔗 https://lnkd.in/deS44n2t #CDMO #Pharma #Partnership #AbiogenPharma

Exciting times for ABIOGEN PHARMA S.P.A. as we expand our footprint in Europe, from Italy to the DACH region: with the acquisition of Altamedics GmbH and EffRx Pharmaceuticals SA we have strengthened our global leadership in the areas of bone metabolism and hypovitaminosis D. Prisca Di Martino, our Chief Commercial Officier, tells us about the commitment to enhancing our portfolio and exploring partnerships to cover new territories globally, actively managing challenges such as American market dynamics to achieve sustained growth. Driven by innovation, the company consistently invests in scientific and clinical research in order to deliver optimal solutions for physicians and patients. #AbiogenPharma

Frankfurt welcomed us with energy, ideas, and meaningful connections during three intense days filled with meetings, exchanges, and shared visions. Our booth at CPHI was much more than an exhibition space, it became a place of connection, storytelling, and forward-looking perspective. Let us share our story through the voices of those who lead our Business Units every day. From general management to research and development, regulatory affairs, international business, and manufacturing, shaping the path toward Abiogen Pharma’s future achievements. Each word is a piece of our journey, each gesture a reflection of our identity. Thank you to everyone who visited us, shared ideas, and contributed to new possibilities. The journey continues, beyond the booths. #AbiogenPharmaGroup #CPHI2025 #CPHIFrankfurt #AtTheHeartOfPharma #PharmaNetworking #PharmaInnovation #PharmaceuticalIndustry #HealthInnovation #PharmaCommunity #GlobalNetworking

Abiogen Pharma will be attending CPHI 2025 in Messe Frankfurt from October 28 to 30. We look forward to welcoming you at our booth 3.0G86, where we will be sharing our latest developments and exploring new partnership opportunities. Whether you are looking to connect over licensing, product innovation, or strategic collaborations, we cannot wait to meet you in person and shape the future of healthcare together. Let’s connect at CPHI 2025! #AbiogenPharma #ItalianRootsGlobalReach #Internationalization #CPHIFrankfurt #AtTheHeartOfPharma